Notice: The AMA office building is closed, and the USAN staff is working from home (WFH) effective March 17, 2020, and will continue until further notice. To all perspective applicants: USAN applications and USAN payments must be sent electronically. Please send all applications to USAN@ama-assn.org. For electronic payment information please contact Mary Haynes (mary.haynes@ama-assn.org) or Brad Wells (brad.wells@ama-assn.org).

The United States Adopted Names (USAN) Council is responsible for selecting simple, informative and unique nonproprietary (generic) drug names. The council and staff meet twice a year to discuss outstanding negotiations, new items of interest and policy issues.

The USAN Council establishes logical nomenclature classifications based on pharmacological and/or chemical relationships. In addition to one member-at-large and a Food and Drug Administration (FDA) liaison, the council consists of one representative from each of the following: The American Medical Association (AMA), United States Pharmacopeia (USP) and the American Pharmacists Association (APhA).

Meeting minutes

The 2020 Winter Meeting of the USAN Council was held Friday, Dec. 4, 2020 virtually via WebEx.
The topics discussed at this meeting included general USAN activities and policy, issues relating to drug nomenclature, and proposed USAN name reviews and recommendations.

All members of the USAN Council were in attendance, as well as members of the USAN Program staff housed at the AMA. Additional observers were present from the United States Pharmacopeia (USP), the World Health Organization (WHO) International Nonproprietary Names (INN) Program and the United States Food and Drug Administration (FDA).

The following items were discussed:

**USAN activities**

- Negotiation stats showed a slight increase flow in adoptions with a slight increase in new submissions.
- USAN Program activities discussed included statistical reports on active negotiations, cumulative adopted names and USAN participation in the INN Program.

**USAN negotiations**

- 40 negotiations discussed: 9 revisions, 12 biologics, 7 multiple round, 8 new negotiations, and 4 INN’s.

**WHO-INN nomenclature and USAN-sponsored applications**

- USAN sponsored 23% of the new INN applications discussed (46 USAN-sponsored applications).
- Revisions were approved for 32 USAN Council names previously recommended.

**USAN policy**

- New stems: 18 approved by the Council.
- Revised stem: 1 approved by the Council.

**USAN website**

- Website statistics included average site views per month, year-to-date totals, average time viewed and demographic information of USAN website visitors.

**Medication error issues**
Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program covering May 1, 2020-Oct. 31, 2020, and cumulative data since May 1, 2002, were discussed.


**USP updates**

USP representative provided information pertaining to USP activities.

**Additional recent updates**

Effective Jan. 1, 2019, there are changes to the conjugated monoclonal antibody naming policy. Visit the monoclonal antibodies page for additional information.

USAN/INN Applicants: Please notify the USAN Program if you have received correspondence from the INN stating that there have been comments and/or objections to the proposed INN name. USAN will be able to eliminate the possibility of having two non-proprietary names for one compound.

New Policy: Effective for the July 2018 USAN Council meeting, only USAN applications for substances that are not proposed or recommended INNs will be reviewed at the USAN Council meetings.

USAN applications for names that have proposed or recommended INNs will be reviewed throughout the year via email by the USAN Council.

Meeting reviews will be reserved for:

- New USAN applications for which no proposed or recommended INNs have been selected
- Multiple round USAN negotiations
- Open-ended (noncompleted) negotiations for which not all USAN Council ballots have been received

New Policy: The USAN Council discussed coining nonproprietary names with 2-letter stems (PDF) at the USANC summer meeting in July 2017. The USAN Council decided that moving forward the new USAN policy (PDF) will be not to coin nonproprietary names with 2-letter stems. The Council based its decision on the likelihood of 2-letter stems creating the potential for medication errors and the inconsistencies in accepting or rejecting proprietary names containing 2-letter stems.

Policy Change: Due to an increase in third-party (non-applicant) requests for stem determinations and the resulting increased demand of USAN staff time, the USAN Program will no longer provide
potential stem reviews for third-party nonproprietary naming consultants who bill their clients for "USAN staff provided" information. USAN Program staff will continue to advise USAN applicants directly.

View the revised USAN stem list.

**AMA headquarters address**

Please send all USAN applications, with checks to:

American Medical Association  
USAN Program  
330 North Wabash Ave., Suite 39300  
Chicago, Illinois 60611-5885

Important Note to Manufacturers: From the date of receiving the adoption notice, a manufacturer has 60 days to review the statement for accuracy, initial and return to the USAN office. After the 60 days expires, with or without an initialed adoption statement, the manufacturer’s adopted USAN will be published on the USAN website after the first of the following month. Any changes, edits or modifications made on the manufacturer’s behalf after the 60-day period will result in a revision/modification fee of $5,000.

**Information for USAN applicants**

The USAN Council primarily negotiates a USAN through rounds of balloting via correspondence. Plus, the council and staff meet twice a year to discuss outstanding negotiations, new items of interest and policy issues.

When nomenclature disputes between the USAN Council and applicants occur and normal procedures fail, the USAN Review Board is the final arbiter. Each sponsoring organization nominates two members, with the boards of trustees of the other sponsoring organizations approving all nominees. Members have no term limits and all Review Board decisions are final and not subject to appeal.

**USAN program information**

URL: https://www.ama-assn.org/about/united-states-adopted-names/usan-council  
Copyright 1995 - 2021 American Medical Association. All rights reserved.
Please use the following contact information to ask general questions about the USAN process.

For questions regarding:

| Cell therapy and gene therapy applications |
| Correct application of stems |
| Scope of USAN |
| INN review procedure |
| Name-selection process |

Contact Stephanie C. Shubat, director at (312) 464-4045 or stephanie.shubat@ama-assn.org.

For questions regarding:

| General information on stems |
| Monoclonal antibodies |
| Organic radicals and counterions |
| USAN modified applications |

Contact Gail Karet, senior scientist at (312) 464-5352 or gail.karet@ama-assn.org.

For questions regarding:

| Contact lens applications |
| Publications |
| Publication deferments |
| USAN procedural inquiries |
| USAN revised applications |
| USAN website inquiries |

Contact Brad Wells, operations manager at (312) 464-4906 or brad.wells@ama-assn.org.

For questions regarding:

| Electronic application submissions |
| Electronic fund transfers |
| General administrative inquiries |
| General status of applications |
| Payment and application address |

Contact Mary Haynes, staff assistant at (312) 464-4046 or mary.haynes@ama-assn.org.
For general information on the USAN program, call (312) 464-4028 or email USAN@ama-assn.org.

USAN newsletter

Read the April 2021 USAN newsletter (PDF).